High affinity human antibodies to human angiopoietin-2

Patent metadata

Field	Value
Publication number	US-10875911-B2
Application number	US-201815907860-A
Country	US
Kind code	B2
Filing date	Feb 28, 2018
Priority date	Jul 29, 2009
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

First claim

What is claimed is:

1. An isolated antibody that specifically binds human angiopoietin-2 (hAng-2), wherein the antibody comprises a heavy chain that comprises a human IgGl constant region or a human IgG4 constant region and a CDR-1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:4, an HCDR-2 comprising the amino acid sequence of SEQ ID NO:6, an HCDR-3 comprising the amino acid sequence of SEQ ID NO:8, a light chain CDR-1 (LCDR-1) comprising the amino acid sequence of SEQ ID NO: 12, an LCDR-2 comprising the amino acid sequence of SEQ II) NO: 14, and an LCDR-3 comprising the amino acid sequence of SEQ ID NO: 16.

2. The isolated antibody of claim 1 , which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 20.

3. The isolated antibody of claim 2 , which comprises a human IgG constant region.

4. The isolated antibody of claim 2 , which comprises a human IgG4 constant region.

5. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier or diluent.

7. A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier or diluent.

8. A pharmaceutical composition comprising the of claim 4 and a pharmaceutically acceptable carrier or diluent.

9. The pharmaceutical composition of claim 7 , which further comprises a vascular endothelial cell growth factor (VEGF) antagonist.

10. The pharmaceutical composition of claim 8 , which further comprises a vascular endothelial cell growth factor (VEGF) antagonist.

11. The pharmaceutical composition of claim 7 , which further comprises a VEGF Trap.

12. The pharmaceutical composition of claim 8 , which further comprises a VEGF Trap.

13. A needle and syringe, pen delivery device or autoinjector delivery device comprising a pharmaceutical composition comprising the antibody of claim 1 or antigen-binding fragment thereof, and a pharmaceutically acceptable carrier or diluent.

14. The needle and syringe, pen delivery device or autoinjector delivery device of claim 13 , wherein the antigen-binding fragment is selected from: a Fab fragment; and a F(ab′)2 fragment.

15. A needle and syringe, pen delivery device or autoinjector delivery device comprising the pharmaceutical composition of claim 7 .

16. A needle and syringe, pen delivery device or autoinjector delivery device comprising the pharmaceutical composition of claim 8 .

17. A needle and syringe, pen delivery device or autoinjector delivery device comprising the pharmaceutical composition of claim 11 .

18. A needle and syringe, pen delivery device or autoinjector delivery device comprising the pharmaceutical composition of claim 12 .

19. An isolated multispecific antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-2 (hAng-2) comprising a first heavy chain variable region comprising a heavy chain CDR-1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:4, an HCDR-2 comprising the amino acid sequence of SEQ ID NO:6, and an HCDR-3 comprising the amino acid sequence of SEQ ID NO:8, and a first light chain variable region comprising CDR-1 (LCDR-1) comprising the amino acid sequence of SEQ ID NO:12, an LCDR-2 comprising the amino acid sequence of SEQ ID NO:14, and an LCDR-3 comprising the amino acid sequence of SEQ ID NO:16; and
a second heavy chain variable region and a second light chain variable region that bind to one or more epitopes that are different from said first variable regions.

20. The multispecific antibody or antigen-binding fragment of claim 19 , which is bispecific.

Assignees

• Regeneron Pharma

Inventors

• Thurston Gavin
• Daly Christopher

Classifications

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title